[go: up one dir, main page]

UY38800A - Receptor de antígeno quimérico (car) anti-hk2 - Google Patents

Receptor de antígeno quimérico (car) anti-hk2

Info

Publication number
UY38800A
UY38800A UY0001038800A UY38800A UY38800A UY 38800 A UY38800 A UY 38800A UY 0001038800 A UY0001038800 A UY 0001038800A UY 38800 A UY38800 A UY 38800A UY 38800 A UY38800 A UY 38800A
Authority
UY
Uruguay
Prior art keywords
chemerical
car
antigen receptor
cars
immunosensitive
Prior art date
Application number
UY0001038800A
Other languages
English (en)
Inventor
Jinquan Luo
Raymond Brittingham
Rajkumar Ganesan
LA PORTE Sherry
T Lee John
Theresa Mcdevitt
Fei Shen
Degang Song
Sathyadevi Venkataramani
Fang Yi
Yonghong Zhao
Sanjaya Singh
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY38800A publication Critical patent/UY38800A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A61K39/00116—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4247—Proteinases
    • A61K40/4249—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente descripción proporciona receptores de antígenos quiméricos (CAR) dirigidos específicamente a la calicreína 2 humana (hK2), y células inmunosensibles que comprenden tales CAR, para el tratamiento del cáncer
UY0001038800A 2019-07-26 2020-07-23 Receptor de antígeno quimérico (car) anti-hk2 UY38800A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962878958P 2019-07-26 2019-07-26
US201962898635P 2019-09-11 2019-09-11
US201962910645P 2019-10-04 2019-10-04
US202063030522P 2020-05-27 2020-05-27

Publications (1)

Publication Number Publication Date
UY38800A true UY38800A (es) 2021-01-29

Family

ID=71895038

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038800A UY38800A (es) 2019-07-26 2020-07-23 Receptor de antígeno quimérico (car) anti-hk2

Country Status (20)

Country Link
US (1) US12071466B2 (es)
EP (1) EP4004055A1 (es)
JP (4) JP2022535150A (es)
KR (1) KR20220040474A (es)
CN (3) CN114174346B (es)
AU (1) AU2020322221A1 (es)
BR (1) BR112022001331A2 (es)
CA (1) CA3148735A1 (es)
CL (1) CL2022000199A1 (es)
CO (1) CO2022000705A2 (es)
EC (1) ECSP22006050A (es)
IL (1) IL289899A (es)
JO (1) JOP20220018A1 (es)
MX (1) MX2022001058A (es)
PE (1) PE20220259A1 (es)
PH (1) PH12022550196A1 (es)
SA (1) SA522431508B1 (es)
TW (1) TW202118792A (es)
UY (1) UY38800A (es)
WO (1) WO2021019386A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
UY38800A (es) 2019-07-26 2021-01-29 Janssen Biotech Inc Receptor de antígeno quimérico (car) anti-hk2
AU2022224508A1 (en) 2021-02-16 2023-10-05 Janssen Biotech, Inc. Materials and methods for enhanced linker targeting
US11766457B2 (en) * 2021-05-14 2023-09-26 The University Of Toledo Immunosuppressive antigen-specific chimeric antigen receptor Treg cells for prevention and/or treatment of autoimmune and alloimmune disorders
IL309179A (en) * 2021-06-10 2024-02-01 Janssen Biotech Inc Nucleic acid coding for KLK2-GPI fusion protein, recombinant cells and their uses
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025250739A1 (en) * 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4452774A (en) 1982-04-30 1984-06-05 President And Fellows Of Harvard College Isonitrile radionuclide complexes for labelling and imaging agents
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
AU2003242820A1 (en) 2002-03-14 2003-09-22 Exonhit Therapeutics S.A. Variants of human kallikrein-2 and kallikrein-3 and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
NZ601171A (en) 2010-03-31 2014-11-28 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
PL2771037T3 (pl) * 2011-10-28 2017-06-30 Fredax Ab Środki terapeutyczne i ich zastosowania
EP2931030B2 (en) 2012-12-14 2024-01-17 OmniAb, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
AU2014351611B2 (en) 2013-11-19 2020-04-23 Janssen Biotech, Inc. Humanised anti kallikrein-2 antibody
GB2520353A (en) * 2013-11-19 2015-05-20 Fredax Ab Antibody polypeptides and uses thereof
US20180326102A1 (en) 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CN110291402B (zh) * 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
JP7088932B2 (ja) * 2016-09-14 2022-06-21 ヤンセン バイオテツク，インコーポレーテツド Ｂｃｍａ特異的フィブロネクチンｉｉｉ型ドメインを有するキメラ抗原受容体、及びその使用
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
AU2018386010A1 (en) * 2017-12-13 2020-05-14 Janssen Biotech, Inc. Immortalized car-T cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
SG11202006606YA (en) 2018-01-12 2020-08-28 Curocell Inc Enhanced immune cells using dual shrna and composition including the same
UY38800A (es) 2019-07-26 2021-01-29 Janssen Biotech Inc Receptor de antígeno quimérico (car) anti-hk2

Also Published As

Publication number Publication date
CN118515779A (zh) 2024-08-20
JP2023052358A (ja) 2023-04-11
JP2023153779A (ja) 2023-10-18
CO2022000705A2 (es) 2022-02-07
CN120842435A (zh) 2025-10-28
BR112022001331A2 (pt) 2022-06-14
TW202118792A (zh) 2021-05-16
AU2020322221A1 (en) 2022-03-24
EP4004055A1 (en) 2022-06-01
CA3148735A1 (en) 2021-02-04
CN114174346B (zh) 2025-08-01
SA522431508B1 (ar) 2025-05-06
ECSP22006050A (es) 2022-02-25
IL289899A (en) 2022-03-01
CL2022000199A1 (es) 2022-10-07
CN114174346A (zh) 2022-03-11
US12071466B2 (en) 2024-08-27
WO2021019386A1 (en) 2021-02-04
JP2022535150A (ja) 2022-08-04
JP7338083B2 (ja) 2023-09-04
JP2025063141A (ja) 2025-04-15
PH12022550196A1 (en) 2022-11-21
KR20220040474A (ko) 2022-03-30
MX2022001058A (es) 2022-02-14
JOP20220018A1 (ar) 2023-01-30
US20220064254A1 (en) 2022-03-03
PE20220259A1 (es) 2022-02-21

Similar Documents

Publication Publication Date Title
UY38800A (es) Receptor de antígeno quimérico (car) anti-hk2
CO2021010075A2 (es) Receptores de antígenos quiméricos de gprc5d y células que los expresan
BR112022008522A2 (pt) Usos de receptores de antígeno quimérico anti-bcma
MX2022003466A (es) Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap).
MX2016013239A (es) Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.
MX2021002316A (es) Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.
PE20252242A1 (es) Receptores de antigeno quimericos dirigidos a cd70
BR112021019411A2 (pt) Métodos para a produção de células car-nk e uso das mesmas
MX2019001469A (es) Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
CL2019002011A1 (es) Anticuerpos anti-tgf-beta y su uso.
MX2017003645A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
CL2022001299A1 (es) Receptores de antígenos quiméricos anti-cd79, células car-t y sus usos.
CO2021010347A2 (es) Células modificadas por receptor de antígeno quimérico para el tratamiento de cánceres que expresan cldn6
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
MX2020009463A (es) Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor.
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
CO2022016866A2 (es) Receptores de antígenos quiméricos dirigidos a cd19 y uso de los mismos
CO2024010826A2 (es) Receptores de antígeno muc16 quiméricos
AR119469A1 (es) Receptor de antígeno quimérico anti-hk2 (car)
DOP2022000014A (es) Receptor de antígeno quimérico (car) anti-hk2
MX2019010941A (es) Receptores de antigeno y usos de los mismos.
CU20220039A7 (es) Combinaciones y kits que incluyen células efectoras inmunitarias modificadas por ingeniería genética para expresar receptores de antígenos